Jun 6, 2025, 10:26 AM by User Not Found

Bio-IT World | Researchers at MIT and Recursion today announced the release of Boltz-2, an updated artificial intelligence model that can predict protein structure (building on Boltz-1) and also binding affinity—how strongly potential drugs bind to their target proteins—in just 20 seconds with a single GPU.

Jun 5, 2025, 15:21 PM by

Phase IIa study results of Rentosertib were published simultaneously in Nature Medicine(IF = 58.7) and presented at the American Thoracic Society (ATS) 2025. Encouraging clinical data showed that patients receiving 60 mg QD Rentosertib experienced the greatest mean improvement in lung function, as measured by forced vital capacity (FVC), with a mean change of +98.4 mL, compared to a mean decline of -20.3 mL in the placebo group. Exploratory biomarkers analyses further validated the biological mechanism of TNIK, the novel target identified through a generative AI approach, supporting Rentosertib’s potential anti-fibrotic and anti-inflammatory effects. Artificial intelligence (AI) is rapidly transforming the pharmaceutical industry, reshaping the landscape from target identification to personalized medicine, and unlocking unprecedented opportunities to accelerate drug discovery and delivery. Despite growing adoption, only a few AI-discovered or AI-designed drug candidates have advanced to clinical trials, and even fewer have demonstrated clinical proof-of-concept.

Jun 5, 2025, 15:21 PM by

Jun 5, 2025, 15:21 PM by

Jun 5, 2025, 15:21 PM by

Jun 5, 2025, 15:21 PM by

Jun 5, 2025, 15:21 PM by

Sionna Therapeutics announces positive data from its Phase 1 clinical trials of SION-719 and SION-451, the company’s nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers, and the company’s next phase of clinical development.

Jun 5, 2025, 15:21 PM by

CluePoints, the premier sponsor of RBQMLive and provider of leading statistical and AI-driven software solutions, has announced the full agenda and expert speaker line up for the 4th annual, award-winning event, RBQMLive.

Jun 4, 2025, 01:00 AM by User Not Found

Bio-IT World | California Institute of Technology researchers have successfully integrated multiple biotechnologies to create the world's first clinically-tested smart bandage system. The iCares smart bandage represents a remarkable fusion of three rapidly advancing biotechnology fields: wearable sensor technology, microfluidics engineering, and machine learning algorithms.

Jun 3, 2025, 08:07 AM by

BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement

Jun 3, 2025, 08:07 AM by

Linus Health Study Champions Person-Centered Brain Health Assessments

Jun 3, 2025, 08:07 AM by

Orbitrap Astral Zoom and Orbitrap Excedion Pro deliver increased speed and sensitivity to set a new performance benchmark for high-resolution, accurate mass spectrometry

Jun 3, 2025, 01:00 AM by User Not Found

Bio-IT World | Although not often counted among the major chronic diseases, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID are both highly prevalent and uniquely challenging because the underlying causes are not fully understood, treatment needs to be personalized, and the often-invisible nature of the symptoms can be stigmatizing.

May 30, 2025, 08:12 AM by

May 30, 2025, 08:12 AM by

The appointment and ongoing science team expansion will help the company advance late-stage liver disease therapeutics

May 30, 2025, 01:00 AM by User Not Found

Bio-IT World | Pathos AI plans to continue investment in their AI foundation model for oncology; Stylus Medicine is emerging from stealth and advancing the company’s in vivo genetic medicines platform and pipeline of in vivo therapeutic programs; and more.

May 29, 2025, 01:00 AM by User Not Found

Bio-IT World | Illumina announced the launch of DRAGEN version 4.4 software; Lupus Research Alliance (LRA) announced the launch of the Lupus Nexus Foundational Analyses; and more.

May 28, 2025, 09:22 AM by

May 28, 2025, 09:22 AM by

Publication showcases the capabilities of Insilico's advanced generative AI platform and integrated workflow in facilitating the rapid development of ISM5939, further demonstrating the potential of AI in drug discovery. Unlike direct STING agonists, ISM5939 precisely modulates the STING pathway within tumor tissues by targeting ENPP1, thereby restoring local immune activation and enhancing anti-tumor immune responses. For the first time, ENPP1 inhibitors have been shown to overcome dual resistance to immune checkpoint inhibitors and chemotherapy, offering a new therapeutic hope for patients with refractory tumors. Since the start of 2025, this marks Insilico Medicine’s third AI-driven drug discovery study published in a Nature sub-journal. Immune checkpoint inhibitors have transformed cancer treatment, providing clinical benefits for a wide range of malignancies. However, only ~10-35% of patients on these treatments achieve a meaningful and durable response, underscoring the urgent need for innovative therapeutic strategies.

May 28, 2025, 09:22 AM by

AMP announced the release of a three-part series of papers on core bioinformatics capabilities for professionals in clinical molecular diagnostic labs.